Scilex Holding (SCLXW) EBITDA Margin (2022 - 2026)
Scilex Holding (SCLXW) recorded quarterly EBITDA Margin of 374.06% in Q1 2026, up 54.67% quarter-over-quarter from 825.12% in Q4 2025, and up 18390.0% on a YoY basis from N/an in Q1 2025.
Scilex Holding (SCLXW) EBITDA Margin (2022 - 2026) Analysis & Trends
Scilex Holding's EBITDA Margin history runs 5 years deep, the most recent figure standing at 374.06% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 18390.0% year-over-year to 374.06%; the TTM figure through Mar 2026 stood at 1112.06% (down 97399.0% YoY), while the FY2025 annual figure was 1223.94%, down 110645.0% from the prior year.
- EBITDA Margin was 374.06% for Q1 2026 at Scilex Holding, up from 825.12% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 8.51% in Q3 2024 to a low of 2469.6% in Q3 2025.
- Historically, EBITDA Margin has averaged 388.69% across 5 years, with a median of 211.8% in 2023.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin surged 34267 bps in 2024, then plunged 246110 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 165.63% in 2022, then increased by 4 bps to 158.97% in 2023, then soared by 78 bps to 34.59% in 2024, then sank by 2285 bps to 825.12% in 2025, then jumped by 55 bps to 374.06% in 2026.
- The last three EBITDA Margin figures came in at 374.06% (Q1 2026), 825.12% (Q4 2025), and 2469.6% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 30.06% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 24.65% |
| 10 | Scilex Holding | - | - | 4.15 Mn | -374.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -374.06% |
| Dec 31, 2025 | -825.12% |
| Sep 30, 2025 | -2,469.60% |
| Jun 30, 2025 | -445.11% |
| Mar 31, 2025 | -557.96% |
| Dec 31, 2024 | -34.59% |
| Sep 30, 2024 | -8.51% |
| Jun 30, 2024 | -218.27% |
| Mar 31, 2024 | -178.96% |
| Dec 31, 2023 | -158.97% |
| Sep 30, 2023 | -351.18% |
| Jun 30, 2023 | -211.80% |
| Mar 31, 2023 | -240.72% |
| Dec 31, 2022 | -165.63% |
| Sep 30, 2022 | -93.31% |
| Jun 30, 2022 | -144.73% |
| Mar 31, 2022 | -129.27% |